Investment Rating - The investment rating for the company is "Buy" (maintained) [2][4]. Core Views - The company is expected to maintain high growth due to its diversified product matrix and channel advantages, with projected net profits for 2024-2026 at 20.82 billion, 27.33 billion, and 35.30 billion respectively, reflecting year-on-year growth rates of 43%, 31%, and 29% [4]. - The company has achieved significant growth in its core brands during the Double 11 shopping festival, with GMV growth rates exceeding 80% and 150% year-on-year [2]. - The company is leading the establishment of industry standards, having officially released the first group standard for fermented ginseng powder, which enhances the standardization in the industry [2][4]. Summary by Sections Financial Performance - The company reported a revenue of 3.524 billion in 2023, with projections of 5.064 billion, 6.803 billion, and 8.922 billion for 2024, 2025, and 2026 respectively, indicating a year-on-year growth of 49% in 2023 and expected growth rates of 44%, 34%, and 31% in the following years [5][9]. - The net profit attributable to the parent company is projected to be 1.452 billion in 2023, increasing to 2.082 billion, 2.733 billion, and 3.530 billion in 2024, 2025, and 2026, with corresponding year-on-year growth rates of 45%, 43%, 31%, and 29% [5][9]. Product Development and Innovation - The company continues to expand its product matrix and has launched new products, including the "Focus Series" cream and the "Order Series," which have received positive market feedback [2]. - The company has invested in R&D, with R&D expenses reaching 0.49 billion in 2024, a 43.2% increase year-on-year, and has obtained 40 new patents, including international invention patents [2][4]. Market Position and Strategy - The company employs a "dual-wheel drive" strategy with its two main brands, which has led to significant sales growth and a balanced revenue structure [2]. - The company is also focusing on the integration of R&D, production, and sales to leverage its technological advantages for long-term growth [2][4].
巨子生物：港股点评：“双11”双核心GMV增长，新标准发布助力行业标准化